NCT06357676View on ClinicalTrials.gov

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2029

Conditions
Mantle Cell Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT scan or FDG PET/CT

PROCEDURE

Echocardiography

Undergo echocardiography

PROCEDURE

FDG-Positron Emission Tomography

Undergo FDG PET/CT

BIOLOGICAL

Glofitamab

Given IV

DRUG

Ibrutinib

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Obinutuzumab

Given IV

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER

NCT06357676 - Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter